Improving patient outcomes in lymphangioleiomyomatosis
Official title: Patient centered outcome measures and prediction tools in lymphangioleiomyomatosis
Funded at University of Cincinnati · NIH-11005214 · Data updated 2026-11-12
This study is looking at a rare lung disease called lymphangioleiomyomatosis (LAM) that mostly affects women, and it aims to create better tools to help doctors predict how the disease might progress and who might not respond well to treatments, so they can provide more personalized care and improve treatment options for patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Cincinnati NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project start | January 1, 2024 |
| Project end | December 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $123,917 |
| NIH project number | 5R21HL172156-02 |
| Project ID | NIH-11005214 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are women diagnosed with lymphangioleiomyomatosis who are experiencing disease progression or have had suboptimal responses to existing treatments.
✕Less likely to help
Patients with LAM who are stable and responding well to current treatments may not benefit from this research.
What this research studies
This research focuses on lymphangioleiomyomatosis (LAM), a rare lung disease primarily affecting women. It aims to develop better prediction tools and outcome measures to help identify patients at risk for disease progression and those who may not respond well to current treatments. By creating a modeling-based prediction system, the research seeks to provide personalized prognostic information that can guide treatment decisions and improve patient care. The study will also explore new clinical outcome assessments to enhance the evaluation of future therapies.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment strategies and improved quality of life for patients with LAM.
How similar studies have gone: Previous research has shown promise in developing predictive tools for other lung diseases, suggesting that this approach could be beneficial for LAM as well.
Where this research is happening
-
University of Cincinnati
Cincinnati, United States Active
Researchers
- Principal investigator: Gupta, Nishant — University of Cincinnati
- Study coordinator: Gupta, Nishant
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.